Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

- Female, Maleergic Rhinitis
- Completed

Study Title: Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Teva Identifier: BDP-AR-101

ClinicalTrials.gov Identifier: NCT01537692

Study Status: Completed

Trial Condition(s): Female, Maleergic Rhinitis

Interventions: Drug: BDP HFA Nasal Aerosol | Drug: BDP HFA Inhalation Aerosol (QVAR)

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 45 Years

Trial Duration: 03/01/2009 - 06/01/2009

Phase: Phase 1

Study Type

Interventional